Robert F. Kennedy Jr., President Trump's nominee to lead HHS, spoke highly of GLP-1 drugs at a Senate confirmation hearing ...

With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...

Discover how tirzepatide, a diabetes drug, offers hope for congenital generalized lipodystrophy (CGL) treatment, potentially ...

Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...

GLP-1 medications such as Ozempic and Wegovy have had a transformative effect for those struggling with weight loss. Many ...

As Stacey Leasca reports for “Food & Wine,” research from Cornell University found that households with at least one GLP-1 ...

For people with diabetes, the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a reduced risk for certain disorders and conditions.

The absolute risk for thyroid cancer is low among patients receiving glucagon-like peptide-1 receptor agonist (GLP-1 RA) ...

A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.

Recent research out of Cornell University showed that GLP-1 users' grocery bills have been reduced by as much as 8.6% — with ...

Ozempic, the drug that was originally approved to treat type 2 diabetes, has now also been approved by the FDA to reduce ...

A new study reports that GLP-1 medications may provide benefits to cognitive and behavioral health, including lowered ...